Russell R G. Bisphosphonates: the first 40 years. Bone 2011; 49: 2-19.

Menschutkin N. Ueber die Einwirkung des Chloracetyls auf phosphorige Säure. Justus Liebigs Ann Chem 1865; 133: 317-320.

Wang J, Goodger N M, Pogrel M A. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003; 61: 1104-1107.

TA161 NI. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. National Institute for Health and Care Excellence (NICE). 2008. Available at https://www.nice.org.uk/guidance/ta161 (accessed May 2023).

Walter C, Al-Nawas B, Grötz K A et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 2008; 54: 1066-1072.

Boonyapakorn T, Schirmer I, Reichart P A, Sturm I, Massenkeil G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 2008; 44: 857-869.

Fehm T, Beck V, Banys M et al. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol 2009; 112: 605-609.

Russell R G. Bisphosphonates: mode of action and pharmacology. Paediatrics 2007; DOI: 10.1542/peds.2006-2023H.

Marx R E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-1117.

Ruggiero S L, Dodson T B, Assael L A, Landesberg R, Marx R E, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws - 2009 update. J Oral Maxillofac Surg 2009; 67: 2-12.

Salesi N, Pistilli R, Marcelli V et al. Bisphosphonates and oral cavity avascular bone necrosis: a review of twelve cases. Anticancer Res 2006; 26: 3111-3115.

Reid I R. Osteonecrosis of the jaw: who gets it, and why? Bone 2009; 44: 4-10.

Ruggiero S L, Dodson T B, Fantasia J et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw - 2014 update. J Oral Maxillofac Surg 2014; 72: 1938-1956.

Ruggiero S L, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102: 433-441.

Khan A A, Morrison A, Hanley D A et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 2015; 30: 3-23.

Ruggiero S L, Woo S-B. Biophosphonate-related osteonecrosis of the jaws. Dent Clin North Am 2008; 52: 111-128.

Migliorati C A, Woo S-B, Hewson I et al. A systematic review of bisphosphonate osteonecrosis (BON) in cancer. Support Care Cancer 2010; 18: 1099-1106.

Saad F, Brown J E, Van Poznak C et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012; 23: 1341-1347.

Tsao C, Darby I, Ebeling P R et al. Oral health risk factors for bisphosphonate-associated jaw osteonecrosis. J Oral Maxillofac Surg 2013; 71: 1360-1366.

Sedghizadeh P P, Stanley K, Caligiuri M, Hofkes S, Lowry B, Shuler C F. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry. J Am Dent Assoc 2009; 140: 61-66.

Lo J C, O'Ryan F S, Gordon N P et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 2010; 68: 243-253.

Zervas K, Verrou E, Teleioudis Z et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 2006; 134: 620-623.

Badros A, Weikel D, Salama A et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006; 24: 945-952.

Bonacina R, Mariani U, Villa F, Villa A. Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients. J Can Dent Assoc 2011; 77: 147.

Vandone A M, Donadio M, Mozzati M et al. Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-centre clinical experience. Ann Oncol 2012; 23: 193-200.

Riaz H, Godman B, Hussain S et al. Prescribing of bisphosphonates and antibiotics in Pakistan: challenges and opportunities for the future. J Pharm Health Serv Res 2015; 6: 111-121.

El Osta L, El Osta B, Lakiss S, Hennequin M, El Osta N. Bisphosphonate-related osteonecrosis of the jaw: awareness and level of knowledge of Lebanese physicians. Support Care Cancer 2015; 23: 2825-2831.

Al-Maweri S A, Alshammari M N, Alharbi A R et al. Knowledge and Opinions of Saudi Dentists Regarding Dental Treatment of Patients Undergoing Bisphosphonates. Eur J Dent 2020; 14: 144-151.

Miranda-Silva W, Montezuma M A, Benites B M, Bruno J S, Fonseca F P, Fregnani E R. Current knowledge regarding medication-related osteonecrosis of the jaw among different health professionals. Support Care Cancer 2020; 28: 5397-5404.

Irshad A, Ramzan M, Iqbal M. Assessment of knowledge about evidence based medicine in medical students and doctors in a Pakistani health care setting. J Ayub Med Coll Abbottabad 2010; 22: 126-129.

Nazir M A, Almas K. Knowledge and practice of evidence-based dentistry among dental professionals: an appraisal of three dental colleges from Lahore, Pakistan. Pak Oral Dent J 2015; 35: 466-471.

Pimolbutr K, Porter S, Fedele S. Osteonecrosis of the Jaw Associated with Anti-Angiogenics in Antiresorptive-Naive Patient: A Comprehensive Review of the Literature. Biomed Res Int 2018; 2018: 8071579.

Allegra A, Innao V, Pulvirenti N, Musolino C. Antiresorptive Agents and Anti-Angiogenesis Drugs in the Development of Osteonecrosis of the Jaw. Tohoku J Exp Med 2019; 248: 27-29.

Tanna N, Steel C, Stagnell S, Bailey E. Awareness of medication related osteonecrosis of the jaws (MRONJ) among general dental practitioners. Br Dent J 2017; 222: 121-125.

Campisi G, Mauceri R, Bedogni A, Fusco V. Re: AAOMS Position paper on Medication-Related Osteonecrosis of the Jaw - 2022 Update. J Oral Maxillofac Surg 2022; 80: 1723-1724.

Scottish Dental Clinical Effectiveness Program. Oral Health Management of Patients at Risk of Medication-related Osteonecrosis of the Jaw. 2017. Available at https://www.sdcep.org.uk/media/tsklutfj/sdcep-oral-health-management-of-patients-at-risk-of-mronj-guidance-in-brief.pdf (accessed January 2023).

Vinitzky-Brener I, Ibáñez-Mancera N-G, Aguilar-Rojas A-M, Álvarez-Jardón A-P. Knowledge of bisphosphonate-related osteonecrosis of the Jawsamong Mexican dentists. Med Oral Patol Oral Cir Bucal 2017; DOI: 10.4317/medoral.21433.

Alhussain A, Peel S, Dempster L, Clokie C, Azarpazhooh A. Knowledge, practices, and opinions of ontario dentists when treating patients receiving bisphosphonates. J Oral Maxillofac Surg 2015; 73: 1095-1105.

De Lima P B, Brasil V L, de Castro J F et al. Knowledge and attitudes of Brazilian dental students and dentists regarding bisphosphonate-related osteonecrosis of the jaw. Support Care Cancer 2015; 23: 3421-3426.

Fosnacht K, Sarraf S, Howe E, Peck L K. How important are high response rates for college surveys? Rev High Educ 2017; 40: 245-265.